With the advent of anti-PD-1 and anti-PD-L1 antibodies, ICIs have become the standard therapy for non-small cell lung cancer (NSCLC) and have improved prognosis3,4. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.